Zombie Unicorns: The Billion-Dollar Startups That Can't Die and Can't Grow.
By Creatives Takeover Editorial Team · October 31, 2026
Not dead. Not alive. Just very, very expensive.
Tonight, kids around the world will dress up as zombies and knock on doors. In Silicon Valley, the zombies don't need costumes. They have offices, payrolls, polished websites and a price tag that once said $1 billion. They still hire, still sell and still post updates on LinkedIn. But they haven't raised new money in years, nobody is lining up to buy them, and the stock market isn't waiting for them either.
Investors have a name for these companies: zombie unicorns. The term used to be a joke at conferences. In 2026 it has become a category, and one of the clearest lessons of the last startup cycle. The story of how so many billion dollar companies ended up walking without going anywhere is also a story about what happens when a valuation runs ahead of the business behind it.
What Makes a Unicorn a Zombie
A unicorn is a private startup valued at $1 billion or more. The word was coined in 2013, when only a few dozen companies qualified and reaching that number felt almost mythical. A valuation is not cash in the bank. It is the price investors agreed to pay for a slice of the company during its last funding round, multiplied out to the whole company. It is a bet on the future, frozen at a single moment.
A zombie unicorn is a company whose bet stopped paying off. It still operates, often with real customers and real revenue. What it cannot do is any of the three things a venture backed company is supposed to do next: raise new money at a higher price, get acquired, or go public. It is too alive to shut down and too stuck to move forward.
There is an important caveat. Not every unicorn that stops raising money is a zombie. Some are profitable and simply don't need more cash. The zombies are the ones that do need capital or an exit, cannot get either at a price their investors accept, and keep going anyway.
How 2021 Built a Herd of Unicorns
To understand the zombies, you have to go back to 2021, the year money was almost free. Interest rates sat near zero, so investors had little to earn from safe assets and poured money into anything growing fast. Venture funds raised record amounts and competed to get into deals, often agreeing to valuations after a single meeting.
The result was a stampede. In 2021 alone, around 340 companies became unicorns, more than in the previous five years combined. At the peak, a new unicorn appeared more than once a day. Research cited by the Chicago Booth Review counted more than 1,100 unicorns after the boom, which together had raised about $700 billion at a combined valuation of around $4 trillion.
Many of those prices assumed the boom would continue. A company growing 100% a year was priced as if it would keep doing so for a decade. Then the conditions changed. In 2022, central banks raised interest rates to fight inflation, public technology stocks fell sharply, and the investors who used to fund late stage startups pulled back. The companies were still valued at 2021 prices, but they now lived in a very different world.
The Numbers Behind the Horde
The data shows how quickly the herd turned. According to PitchBook figures reported by Axios in March 2026, 38.3% of the 909 active unicorns in the United States had not raised any funding in the previous three years. In 2022, that share was just 2.3%. It climbed to about 20% in 2024 and to 33.5% in 2025. In four years, the share of stalled unicorns grew more than sixteenfold.
The global picture is similar. Ilya Strebulaev, a Stanford professor who tracks around 1,900 unicorns, found that by May 2026, 332 had raised money at or below their peak valuation, and 383 had disclosed no new funding in three years. Forty one had already lost their unicorn status. PitchBook expects between $500 billion and $1 trillion in valuation cuts as these companies are forced to reprice.
The 2021 class looks worst of all. Carta, which manages ownership records for tens of thousands of startups, followed 616 companies that became unicorns in 2020 and 2021. By January 2025, 374 of them, about six in ten, had not raised a single new round. Only 78 had exited through an IPO or acquisition. Just 14 had officially shut down. The gap between those who stopped raising and those who closed their doors is where the zombies live.
Why a Zombie Can't Simply Die
If a company is stuck, why not wind it down and move on? Because almost everyone involved has a reason to avoid that decision.
Investors have the first reason. Venture funds report the value of their holdings to the people who gave them money, known as limited partners. As long as a startup hasn't raised a new round, the fund can often keep it on the books near its last price. Shutting the company down turns a paper value into a real loss, and that loss shows up in the fund's performance just as it is trying to raise its next fund.
Founders have the second reason. Many have spent close to a decade on the company. They announced the billion dollar valuation in public, hired people on the promise of it and built their identity around it. Walking away feels like admitting it was never real.
The third reason is that many zombies still have a business. Jason Lemkin of SaaStr points out that some of the stalled 2021 unicorns have more than $100 million in annual recurring revenue, the yearly subscription income a software company can count on. Their problem is that growth has slowed to under 20% a year. That is a healthy company by most standards. It is just not a company worth what it was priced at.
The fourth reason is structural. Venture agreements often give investors the right to veto an IPO. A listing at a lower price would reveal the real value of the company in public, so investors who paid the high price can block it, even when going public might be the most sensible way forward.
Why a Zombie Can't Grow Either
The same valuation that once felt like a crown now works like a curse. Raising new money means accepting a down round, a funding round at a lower price than the last one. A down round dilutes existing shareholders, damages the company's reputation and often wipes out the value of employee stock options. More than 100 unicorns were last valued at exactly $1 billion, according to CB Insights, so any cut at all would cost them the title they built their story on.
There is also a hidden weight called a liquidation preference. Most late stage investors negotiate the right to get their money back first if the company is sold. If a startup raised $500 million and sells for $500 million, the investors may take almost everything, and founders and employees may walk away with close to nothing. That makes many buyers and many founders uninterested in a sale, even a reasonable one.
Talent is the next problem. When stock options are worth less than the price employees would pay to exercise them, the best engineers and salespeople have little reason to stay. Many leave for newer companies where their equity still has a chance to grow, which makes growth even harder for the ones left behind.
Finally, the money has moved on. Investors are pouring capital into artificial intelligence. AI companies now account for nearly half of the total value of all unicorns, according to PitchBook. A meal kit, fitness or workplace software company priced in 2021 is simply not where investors want to be.
A Zombie in Slow Motion
To picture how this works, imagine a fitness app valued at $1.2 billion in a 2021 funding round. This is an illustration, not a real company. That year, it grew 150% as people exercised at home. In 2022, gyms reopened and growth fell to 30%. The company cut its marketing budget, froze hiring and stretched its cash to last three more years.
By 2024, it has $90 million in yearly revenue and is close to breaking even. Investors would value a company like that at perhaps $400 million. Raising money at that price would crush employee options and trigger painful terms for earlier investors. Selling the company would mostly pay back the late stage investors first. Going public would announce the drop to the world. So the board does nothing. The company keeps operating, the best people quietly leave, and every year the gap between its old price and its real value becomes harder to close. Nobody decided to become a zombie. It happened one postponed decision at a time.
The Ways Out
Zombie status doesn't have to be permanent. Companies have a few real ways out, and none of them are painless.
The first is to accept the reset. Some companies raise a down round, rebuild employee options at the new price and start growing again from an honest number. It hurts, but it gives the company a fresh start.
The second is to sell. Private equity firms and larger competitors are buying stalled startups, especially ones with steady revenue and low spending. Lemkin's advice to these companies is simple: keep growing, stop burning cash and keep customers renewing, and there will be a buyer, maybe not at the old price but at a real one.
The third is to change direction. Some companies pivot toward AI or a narrower, more profitable market. A few succeed. Many more just change their pitch.
The fourth is to close with dignity. Winding down returns whatever cash is left to investors and frees founders and employees to build something new. It is the option nobody wants to talk about, and often the one that costs the least in the long run.
Even AI Is Not Immune
It would be easy to see zombie unicorns as a leftover from 2021. They aren't only that. Several AI companies that reached billion dollar valuations in 2022 and 2023, including general purpose model builders such as Adept and Inflection, have not raised money at a higher price since. Today's hottest sector is producing its own early zombies, for the same reason as before: prices set on expectations that the business could not keep up with.
What a Founder Can Take From the Zombie Unicorns
- Treat a valuation as a promise, not a prize.
Every dollar of valuation is a number you will have to grow into later. A smaller round at a fair price leaves room to win.
- Chase traction, not headlines.
Customers who pay and stay are the only thing that compounds. A press release about your round does not.
- Raise for milestones, not for status.
Rounds are taking longer than they used to. Carta found that the median time between a seed round and a Series A had stretched to more than 20 months, and it now advises founders to plan for 24 to 30 months of runway. Raise what you need to reach the next proof point.
- Read the terms, not just the number.
Liquidation preferences and other investor rights decide who gets paid in a sale. A higher valuation with harsher terms can be worth less to you than a lower one with clean terms.
- Set a decision date.
Agree in advance what results by what date mean continue, change course or stop. Zombies are not created by one bad decision. They are created by decisions that never get made.
- Don't build in isolation.
Zombies survive because nobody asks the uncomfortable question. Surround yourself with founders who will ask every week whether what you are building is still working, and who will tell you honestly when it isn't.
You don't need a billion dollar valuation to become a zombie. A side project you haven't touched in months, a product stuck in "almost ready," a startup with no users and no plan: it is the same condition at a smaller scale.
So this Halloween, look honestly at what you are building. Is it growing, or just walking? The scariest outcome isn't failure. It's spending years in between.